nib holdings limited

The Business

nib is Australia's third-largest private health insurer, operating in a market effectively controlled by two players alongside Medibank Private. Australian Residents health cover generated $3,013m of FY26 revenue, roughly 80% of the group. New Zealand insurance contributed $429m (11%), international student and visa cover $237m (6%), and NDIS-related Thrive and Health Services businesses the remainder. Regulatory licensing under APRA and capital adequacy rules protect this structure: no new entrant has meaningfully challenged the incumbents in decades.

Recent Performance

FY26 revenue reached $3,767m with net profit of $185m, a result depressed by one-off items and a weak New Zealand contribution earlier in the turnaround. The standout was New Zealand's underlying operating profit swinging from a $3m loss to a $28m profit, the largest single earnings driver in the year, on the back of a 25.5% price increase pushed through the annual premium cycle. Management also completed the sale of the Travel insurance business, simplifying the portfolio.

Outlook

Revenue growth is expected to ease over the next few years as premium increases and policyholder growth normalise from currently elevated levels. Earnings margins should expand modestly as expense discipline continues and the New Zealand recovery feeds through more fully. Earnings per share growth in the coming financial year is set to look strong, but that reflects a low prior-year comparison base rather than a step-change in profitability; growth should then settle to a more moderate, representative annual pace as the base normalises.

Key Risks

The discount rate applied to nib's regulated, defensive earnings stream is the single biggest swing factor in how the market prices this stock, more influential than any operating variable management controls. A rejection from the NDIS provider panel, a decision due in October 2027, would trigger an impairment and an ongoing loss of Thrive segment earnings, though nib's scale gives it a reasonable case for selection. Separately, risk equalisation, the industry-wide mechanism that redistributes claims costs between insurers, compressed nib's Australian gross margin meaningfully in FY26, and continued volatility here would pressure underwriting margins further. None of these risks reflects poor execution; they are structural features of operating in a regulated, mechanism-driven industry.

What to Watch

The thesis-defining event is the first-half FY27 result in February 2027, which will confirm whether New Zealand's margin recovery is structural and whether Australian policy lapse rates are stabilising.

• Oct-Dec 2026 Travel sale completion & capital return decision — proceeds create scope for a special dividend or buyback.
• Oct 2027 NDIS panel selection announcement — a binary outcome for the Thrive business.

Company Description

nib operates four segments. Australian Residents health insurance is the core, generating around 80% of group revenue ($3,013m in FY26) from policies sold direct, via brokers, and through whitelabel partners. New Zealand insurance contributes roughly 11% ($429m), recently turned around through decisive repricing. International health cover for students and temporary visa holders adds about 6% ($237m), a segment tied to immigration policy. The remainder comes from Thrive and Health Services, smaller businesses built around National Disability Insurance Scheme (NDIS) support and broader health management services.

Where the Growth Is

New Zealand is the clearest earnings driver right now. Underlying operating profit swung from a $3m loss to a $28m profit in FY26, the largest single contributor to group earnings growth. A 25.5% price increase is locked into the annual premium cycle, and claims inflation has moderated from around 15% to 12%. Whether this margin recovery proves structural rather than a one-off pricing catch-up is a key open question, and one the market has not fully resolved either way.

Competitive Position

nib's roughly 10% share of the Australian private health insurance market has held stable for over 70 years, protected by APRA licensing requirements and capital adequacy rules that make new entry impractical. Alongside Medibank Private, the two listed insurers dominate an industry where switching is friction-heavy: policyholders face financial penalties (the Medicare Levy Surcharge and Lifetime Health Cover loading) for lapsing or delaying cover, which anchors retention even as comparison-site-driven shopping between insurers increases. These advantages are durable over a five-to-seven year horizon rather than indefinitely widening; nib is not gaining share, it is defending a stable position.

Management & Capital Discipline

Management divested the Travel insurance business at roughly seven times earnings, redirected proceeds toward debt reduction, and lifted the dividend payout target range to 65-75%. Guidance has been met consistently over the past year. One flag worth noting: the Board's own self-assessment rated its risk management framework as below threshold, an unusual admission that sits awkwardly against otherwise solid operational execution and warrants monitoring rather than dismissal.

Financial Position

nib carries minimal net debt following the Travel sale and generates operating cash flow comfortably ahead of its capital spending needs, with forecast free cash flow of $236m in FY27 against capital expenditure of just $40m. Return on equity of 16.1% and return on invested capital of 13.9% both sit above the cost of funding the business. As a regulated insurer required to hold capital above prudential minimums, nib is well placed to absorb a period of underwriting margin pressure without balance sheet stress.